Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lesion-by-lesion versus field MAL-PDT for actinic keratosis prevention
NL-OMON57756Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Relapse rate of actinic keratosis and incidence of new lesions at 9 months after photodynamic therapy and Time to new lesion development. Planned start Dec 2011; status: withdrawn.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NL-OMON57756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57756.